$MFIN

Medallion Financial to Repurchase $15 Million Trust Preferreds for $11.05 Million, Adds Standstill With ZimCal

Medallion Financial (MFIN) agreed to repurchase $15M trust preferred securities from BIMIZCI for $11.05M, including accrued distributions. The deal includes a standstill agreement until 2031 and a requirement for investors to dispose of all Medallion securities by 2026.

Original reporting
Published Oct 19, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medallion Financial to Repurchase $15 Million Trust Preferreds for $11.05 Million, Adds Standstill With ZimCal — source image
Decision brief

The 30-second read

$MFINBullishLow
01

Why it matters

The transaction reduces preferred debt and may slightly improve equity valuation, though the modest size limits broader market impact.

02

Market read

A small‑scale buyback of preferred securities that may provide modest price support for MFIN common shares.

03

What to watch

Potential future standstill restrictions could affect liquidity for preferred holders.

Relevance 5/10Novelty 5/10Timing: post‑filing

Background

Medallion Financial disclosed a trust preferred repurchase agreement with BIMIZCI Fund and ZimCal Asset Management, including a long‑term standstill.

Company-level read

Ticker impact

$MFINBullishMedium confidence
Context

MFIN filed an 8‑K announcing a $15 M trust preferred repurchase at $11.05 M, a primary corporate action for the company.

Expected impact

likely modest upward pressure as the market prices in the buyback discount

Evidence & confidence

Buybacks at a discount signal management confidence and improve capital structure, but the small absolute amount limits impact.

Market effects

Minimal effect on the broader financial services sector.

Limited to U.S. small‑cap investors.

None

Counterpoint

The repurchase may be a cash drain with limited upside for shareholders.

Key entities

  • Medallion Financial

    Issuer of the trust preferred securities.

  • BIMIZCI Fund

    Counterparty purchasing the preferreds.

  • ZimCal Asset Management

    Co‑counterparty in the agreement.

Related articles

$MFINMed

MEDALLION FINANCIAL CORP. REPORTS 2026 SECOND QUARTER RESULTS

MEDALLION FINANCIAL CORP (MBNKO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE: MEDALLION FINANCIAL CORP. REPORTS 2026 SECOND QUARTER RESULTS Record Assets Surpass $3.0 billion, Loan Originations Increase 63% NEW YORK, NY – July 29, 2026 – Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”), a specialty

$MFINHighAI 9/10

Medallion Financial Corp. Urges Shareholders to Vote for Its Highly Qualified Director Nominees Ahead of 2026 Annual Meeting

Medallion Financial Corp. (NASDAQ: MFIN) urged shareholders to vote on the “WHITE” universal proxy card for three director nominees—John Everets, Cynthia A. Hallenbeck, and Alvin Murstein—ahead of its 2026 annual meeting. The company said ZimCal, led by Stephen Hodges, is seeking a premium buyout of Medallion trust preferred shares and has waged three proxy fights in three years. Medallion cited 2021–2025 growth, including $2.5 billion consumer loans and $266 million net income over five years.

$RCUSHigh

Arcus Biosciences stock falls on public offering announcement

Arcus Biosciences (NYSE:RCUS) shares fell 6.6% in after-hours trading after announcing a public offering of common stock. The company plans to sell shares, with underwriters having a 30-day option for additional shares. Shares had already dropped 20% during regular trading. Citi analyst Yigal Nochomovitz maintained a Buy rating and $50.00 price target, noting clinical trial results met market expectations.